What are intracranial germ cell tumours?
Intracranial germ cell tumours (CNS GCTs) are rare brain tumours that mainly affect children, teenagers and young adults. They develop from germ cells, the cells that normally form eggs and sperm. During early development in the womb, a few of these cells are thought to end up in the middle of the brain instead of in the ovaries or testes.
These tumours almost always grow near the centre of the brain. The two main sites are the pineal gland, at the back of the third ventricle, and the suprasellar region, just above the pituitary gland.
There are two main groups:
- Germinoma, the most common type, which is very sensitive to radiotherapy and chemotherapy
- Non-germinomatous germ cell tumours (NGGCTs), such as yolk sac tumour, embryonal carcinoma, choriocarcinoma and mixed tumours, which need more intensive treatment
The outlook is generally good. More than 9 in 10 people with a germinoma are cured. The main long-term challenge is managing hormone problems and other late effects of the tumour and its treatment.
1. Key facts at a glance
| Feature | Details |
|---|---|
| How common | About 3-4% of childhood brain tumours in Europe and North America; up to about 10-15% in East Asia (Japan, Korea, China, Taiwan) |
| Typical age | Peak between 10 and 19 years; most occur before age 30 |
| Sex | Overall about 2-3 times more common in males; pineal tumours are mostly in boys, while suprasellar tumours affect both sexes about equally |
| Main sites | Pineal region (about 45%), suprasellar region (about 30-35%), both at once (“bifocal”, about 5-10%), basal ganglia and thalamus (about 5-10%) |
| Commonest type | Germinoma, about two-thirds of cases |
| Key tests | MRI of the brain and spine; AFP and beta-hCG tumour markers in blood and spinal fluid |
| Outlook | Germinoma: over 90% cured. NGGCT: about 70-80% cured with modern treatment |
2. Types of intracranial germ cell tumour
| Type | Tumour markers | Notes |
|---|---|---|
| Pure germinoma | AFP normal; beta-hCG normal or only mildly raised | The most common type; the same cell type as seminoma of the testis and dysgerminoma of the ovary |
| Mature teratoma | Normal | Contains mature tissues such as skin, hair or cartilage; mainly treated by surgery |
| Immature teratoma | Usually normal | Contains immature tissue; behaves more aggressively |
| Yolk sac tumour | High AFP | A non-germinomatous malignant type |
| Embryonal carcinoma | Usually normal | A non-germinomatous malignant type |
| Choriocarcinoma | Very high beta-hCG | Can bleed; a non-germinomatous malignant type |
| Mixed germ cell tumour | Depends on parts present | Contains two or more of the above |
Doctors often group them as “secreting” (high markers) or “non-secreting” tumours. Tumours with clearly raised markers are treated as NGGCTs.
3. Causes and risk factors
The cause is not fully understood. The tumours are thought to come from germ cells or primitive stem cells left in the midline of the brain.
| Factor | Notes |
|---|---|
| Gene changes in the tumour | Changes in the KIT/RAS signalling pathway are common, especially in germinomas |
| Klinefelter syndrome (47,XXY) | Increases the risk |
| Down syndrome | Linked to a higher risk |
| East Asian ancestry | Higher rates, probably due to inherited genetic factors |
| Lifestyle | No known lifestyle or environmental cause |
Most children with a CNS GCT have no inherited condition, and brothers and sisters are not at increased risk.
4. How does it look?
4.1 Signs a doctor may see
| Sign | What it looks like |
|---|---|
| Parinaud syndrome | Difficulty looking upwards, pupils that react poorly to light but better to near focus, and jerky eye movements when trying to look up; typical of pineal tumours |
| Swollen optic discs | Seen on eye examination when pressure in the head is raised |
| Short stature or slow growth | From low growth hormone |
| Early or delayed puberty | Early puberty can occur in boys when the tumour makes beta-hCG; delayed or stalled puberty from pituitary damage |
| Visual field loss | Loss of side vision from pressure on the optic nerves |
| Weakness on one side | With tumours in the basal ganglia or thalamus |
4.2 On MRI
| Feature | Typical finding |
|---|---|
| Pineal germinoma | A solid mass behind the third ventricle that enhances with contrast, often blocking the fluid pathway and causing hydrocephalus |
| Suprasellar germinoma | Thickening of the pituitary stalk or a mass above the pituitary; the normal bright spot of the posterior pituitary may be missing |
| Bifocal tumours | Pineal and suprasellar tumours at the same time; very suggestive of germinoma |
| Basal ganglia germinoma | A subtle, ill-defined lesion with little swelling; may cause shrinkage of the brain on one side |
| NGGCT and teratoma | More often mixed solid and cystic, with fat, calcium or bleeding |
| Spinal MRI | Checks for spread along the spinal fluid (“drop metastases”) |
4.3 Under the microscope
| Feature | Germinoma |
|---|---|
| Cells | Large, round cells with clear cytoplasm and big nucleoli |
| Background | Many small lymphocytes, sometimes with granulomas, which can make small biopsies look like inflammation |
| Markers | Positive for OCT3/4, KIT (CD117), PLAP and SALL4; negative for AFP and cytokeratin. Scattered hCG-positive giant cells may be seen |
5. Symptoms
Symptoms depend on where the tumour is. They may develop over weeks, or slowly over months or even years.
5.1 Pineal region tumours
| Symptom | Cause |
|---|---|
| Headache, often worse in the morning | Raised pressure from blocked spinal fluid (hydrocephalus) |
| Nausea and vomiting | Raised pressure |
| Double vision or trouble looking up | Pressure on the midbrain (Parinaud syndrome) |
| Drowsiness, unsteadiness, poor concentration | Raised pressure |
5.2 Suprasellar tumours
| Symptom | Cause |
|---|---|
| Extreme thirst and passing large amounts of urine | Diabetes insipidus, from loss of the hormone vasopressin. It is often the first symptom and may appear months or years before a tumour is seen on MRI |
| Slow growth | Low growth hormone |
| Delayed, stopped or early puberty; missed periods | Pituitary hormone problems |
| Tiredness, weight changes, feeling cold | Low thyroid or adrenal hormones |
| Blurred vision or loss of side vision | Pressure on the optic nerves |
5.3 Basal ganglia and thalamic tumours
| Symptom | Cause |
|---|---|
| Weakness of an arm or leg | Damage to movement pathways |
| Changes in school performance or behaviour | Effect on thinking and memory |
| Movement problems | Involvement of the basal ganglia |
5.4 When to see a doctor urgently
Seek urgent medical advice for a child or young person with:
- headaches with vomiting, especially in the morning
- new double vision or difficulty looking up
- excessive thirst and urination, particularly with slow growth or puberty changes
- loss of vision or new weakness
6. Diagnosis
| Test | Purpose |
|---|---|
| MRI of the brain and whole spine | Shows the tumour and any spread along the spinal fluid |
| Serum AFP and beta-hCG | Tumour markers in blood |
| Spinal fluid (CSF) markers and cytology | Lumbar puncture when safe, to measure markers and look for tumour cells |
| Hormone tests | Checks for diabetes insipidus and low pituitary hormones, which need replacing quickly, especially cortisol |
| Eye and vision tests | Records vision and visual fields |
| Biopsy | Needed when markers are normal or only mildly raised. Often done endoscopically, sometimes together with an operation to relieve hydrocephalus (endoscopic third ventriculostomy) |
6.1 When a biopsy is not needed
If AFP and/or beta-hCG are clearly raised in blood or spinal fluid, the tumour is diagnosed as a secreting NGGCT without a biopsy. Treatment can start straight away. Exact cut-off levels differ slightly between European (SIOP) and North American (COG) protocols.
If markers are normal, a biopsy is essential. Imaging alone cannot reliably separate germinoma from other tumours or from inflammatory conditions.
7. Treatment
Treatment is given in a specialist children’s or teenage and young adult neuro-oncology centre. Surgery to remove the tumour is usually not needed for germinoma, because it responds so well to radiotherapy and chemotherapy.
7.1 Germinoma
| Situation | Usual treatment |
|---|---|
| Localised germinoma | Chemotherapy (usually carboplatin and etoposide) followed by reduced-dose radiotherapy to the fluid spaces of the brain (whole-ventricular radiotherapy, about 18-24 Gy). The final SIOP CNS GCT II report (2026) showed that the extra boost to the tumour site can safely be left out in patients in complete remission after chemotherapy |
| Alternative for localised germinoma | Radiotherapy alone to the brain and spine (craniospinal irradiation, 24 Gy) with a tumour boost; very effective but with more late effects |
| Metastatic germinoma | Craniospinal radiotherapy, with or without chemotherapy |
| Basal ganglia germinoma | Treated similarly; the target volume is adjusted |
Chemotherapy alone, without radiotherapy, leads to a high relapse rate and is not recommended outside trials.
7.2 Non-germinomatous germ cell tumours
| Step | Details |
|---|---|
| Chemotherapy | Usually 4 cycles of platinum-based chemotherapy, such as cisplatin, etoposide and ifosfamide |
| Second-look surgery | To remove any remaining mass, which may contain teratoma |
| Radiotherapy | Focal or craniospinal radiotherapy depending on the protocol and spread |
| Relapse | High-dose chemotherapy with stem cell rescue may be used |
7.3 Teratoma
Mature teratomas are treated with surgery. Sometimes a mass grows during chemotherapy while markers fall, called growing teratoma syndrome. This needs surgery, not more chemotherapy.
7.4 Supportive care
| Need | Help |
|---|---|
| Hydrocephalus | Endoscopic third ventriculostomy or a shunt |
| Diabetes insipidus | Desmopressin tablets or spray, with careful fluid balance |
| Low cortisol | Hydrocortisone, with extra doses during illness |
| Other hormones | Thyroid hormone, growth hormone and sex hormones as needed |
| Hearing | Hearing tests during cisplatin treatment |
8. Outlook (prognosis)
| Tumour type | Approximate 5-year survival |
|---|---|
| Localised germinoma | Over 95% |
| Metastatic germinoma | About 90% |
| Secreting NGGCT | About 70-80% |
| Relapsed germinoma | Many can still be cured with further chemotherapy and radiotherapy |
Very high AFP levels and remaining tumour after treatment are linked to a worse outlook in NGGCT.
9. Late effects and follow-up
Many survivors live long, healthy lives, but lifelong follow-up is important.
| Late effect | Notes |
|---|---|
| Hormone problems | Very common, especially with suprasellar tumours. Diabetes insipidus is often permanent. Lifelong hormone replacement may be needed |
| Fertility | May need hormone treatment to start puberty or to conceive; fertility preservation is discussed before treatment where possible |
| Thinking and memory | Problems with attention, processing speed and memory, more likely after larger radiotherapy fields |
| Hearing loss | After cisplatin |
| Vision | Lasting visual field loss in some |
| Second tumours and stroke | A small increased risk years after radiotherapy |
| Weight gain | Damage to the hypothalamus can increase appetite |
| What | How often |
|---|---|
| MRI scans | Every 3-6 months at first, then yearly |
| Tumour markers | At each visit for secreting tumours |
| Endocrinology review | Lifelong |
| Neuropsychology and school support | As needed |
10. Frequently asked questions
| Question | Answer |
|---|---|
| Is a germinoma cancer? | Yes, it is a malignant tumour, but it is one of the most curable brain tumours |
| Is it the same as testicular cancer? | It is the same cell type as seminoma, but it grows in the brain and is treated by brain tumour specialists |
| Why is thirst so important? | Diabetes insipidus can be the first sign of a suprasellar germinoma, sometimes long before the tumour is visible |
| Will my child need an operation? | Usually only a small biopsy and, if needed, an operation to relieve hydrocephalus. Big operations are rarely needed for germinoma |
| Will my child have normal puberty? | Many need hormone treatment, which can usually bring on normal puberty |
Resources
- Louis, D.N. et al. (2021) ‘The 2021 WHO classification of tumors of the central nervous system: a summary’, Neuro-Oncology, 23(8), pp. 1231-1251.
- Murray, M.J. et al. (2015) ‘Consensus on the management of intracranial germ-cell tumours’, The Lancet Oncology, 16(9), pp. e470-e477.
- Frappaz, D. et al. (2022) ‘EANO, SNO and Euracan consensus review on the current management and future development of intracranial germ cell tumors in adolescents and young adults’, Neuro-Oncology, 24(4), pp. 516-527.
- Echevarria, M.E., Fangusaro, J. and Goldman, S. (2008) ‘Pediatric central nervous system germ cell tumors: a review’, The Oncologist, 13(6), pp. 690-699.
- Bowzyk Al-Naeeb, A. et al. (2018) ‘Current management of intracranial germ cell tumours’, Clinical Oncology, 30(4), pp. 204-214.
- Calaminus, G. et al. (2013) ‘SIOP CNS GCT 96: final report of outcome of a prospective, multinational nonrandomized trial for children and adults with intracranial germinoma, comparing craniospinal irradiation alone with chemotherapy followed by focal primary site irradiation for patients with localized disease’, Neuro-Oncology, 15(6), pp. 788-796.
- Calaminus, G. et al. (2026) ‘Final report of the SIOP-CNS-GCT II protocol for germinoma: omitting radiotherapy boost is safe in localized disease in complete remission after chemotherapy’, Neuro-Oncology, 28(9), pp. 2234-2247.
- Kortmann, R.D. (2014) ‘Current concepts and future strategies in the management of intracranial germinoma’, Expert Review of Anticancer Therapy, 14(1), pp. 105-119.
- Wang, L. et al. (2014) ‘Novel somatic and germline mutations in intracranial germ cell tumours’, Nature, 511(7508), pp. 241-245.
- Takami, H. et al. (2019) ‘Integrated clinical, histopathological, and molecular data analysis of 190 central nervous system germ cell tumors from the iGCT Consortium’, Neuro-Oncology, 21(12), pp. 1565-1577.
- National Cancer Institute (2026) Childhood Central Nervous System Germ Cell Tumors Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/brain/hp/child-cns-germ-cell-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.